Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma.
Ilaria SaltarellaVanessa DesantisAssunta MelaccioAntonio Giovanni SolimandoAurelia LamanuzziRoberto RiaClelia Tiziana StorlazziMaria Addolorata MariggiòAngelo VaccaMaria Antonia FrassanitoPublished in: Cells (2020)
Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients undergo progression. Dara exerts anti-MM activity via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and immunomodulatory effects. Deregulation of these pleiotropic mechanisms may cause development of Dara resistance. Knowledge of this resistance may improve the therapeutic management of MM patients.
Keyphrases
- end stage renal disease
- multiple myeloma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- healthcare
- clinical practice
- stem cells
- endothelial cells
- cell proliferation
- patient reported outcomes
- machine learning
- electronic health record
- mesenchymal stem cells
- cell cycle
- deep learning
- bone marrow
- data analysis
- cell therapy
- combination therapy